BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 18224704)

  • 21. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
    Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
    Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
    Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
    Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
    Al-Soud YA; Bey E; Oster A; Marchais-Oberwinkler S; Werth R; Kruchten P; Frotscher M; Hartmann RW
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):212-5. PubMed ID: 18848601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Messinger J; Hirvelä L; Husen B; Kangas L; Koskimies P; Pentikäinen O; Saarenketo P; Thole H
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):192-8. PubMed ID: 16413669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active site analysis of 17beta-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT.
    Alho-Richmond S; Lilienkampf A; Wähälä K
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):208-13. PubMed ID: 16412556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Reed MJ; Potter BV
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):204-7. PubMed ID: 16337736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
    Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
    Day JM; Tutill HJ; Purohit A; Reed MJ
    Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
    Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
    Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
    Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
    ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
    Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
    J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.